NUPLAZID has a monopoly in Parkinson's disease psychosis — no direct competitors. DAYBUE for Rett syndrome is a rare disease franchise. 90.8% gross margins, 11.8x P/E, profitable with $2.21 EPS. CNS specialty niche with regulatory barriers to entry.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$4.45BSnapshot value
NUPLAZID Parkinson's psychosis market expansion (diagnosis rate improvement), DAYBUE Rett syndrome revenue ramp, pipeline readout in Alzheimer's psychosis / schizophrenia adjunct, potential M&A target for larger CNS player
1. NUPLAZID growth ceiling — Parkinson's psychosis TAM smaller than modeled. 2. DAYBUE Rett syndrome commercial disappointment. 3. Alzheimer's psychosis Ph3 failure. 4. Generic pimavanserin challenge post-LOE. 5. CMS pricing pressure on specialty CNS drugs.
Low retail interest — boring CNS biotech. High institutional ownership (99%) signals professional conviction.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed